$TBPH News

Last published 3mo ago

3mo agoTBPHTheravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second...
4mo agoZYME TBPHZymeworks to Acquire Theravance Biopharma, Inc.GlobeNewswireAcquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance
4mo agoTBPHTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (Nasdaq: TBPH) today announced that it has entered into a definitive agreement...
6mo agoTBPHTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first...
7mo agoTBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth...
8mo agoTBPHTheravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ActionsPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study...
11mo agoTBPHTheravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8,...
11mo agoTBPHTheravance Biopharma to Participate in Upcoming Investor ConferencesPR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:...
1y agoTBPHTheravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third...
1y agoTBPHTheravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous SystemPR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous...
1y agoTBPHTheravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on...
1y agoTBPHTheravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System AtrophyBusiness WireTheravance Biopharma, Inc. (NASDAQ:TBPH) today announced the launch of "Power in the Periphery," a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen scientific
1y agoTBPHTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual MeetingPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire...
1y agoTBPHTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment...
1y agoTBPHTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System AtrophyPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label...
1y agoTBPHTheravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoTBPHTheravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second...
1y agoTBPHTheravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at...
1y agoTBPHTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPAPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that Viatris Inc. ("Viatris"), has secured...
1y agoTBPH GSKTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 MillionPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New ...
1y agoTBPHTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA CongressPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3...
1y agoTBPHTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first...
1y agoTBPHTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA CongressPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of...
1y agoTBPHTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on...
1y agoTBPHTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual MeetingPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las...
1y agoTBPHTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of NeurologyPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of...
1y agoTBPHTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial ResultsPR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50...
1y agoTBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12...
1y agoTBPHTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferencePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold...
1y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 ...
1y agoTBPHTheravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoTBPHTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValuePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third...
2y agoTBPHTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on...
2y agoTBPHTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseasePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal...
2y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New...
2y agoTBPHTheravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoTBPHTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the second...
2y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at...
2y agoTBPHTheravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on...
2y agoTBPHTheravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoTBPHTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdatePR NewswireTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first...
2y agoTBPHTheravance Biopharma to Participate in an Upcoming Investor ConferencePR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...
2y agoTBPHTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024PR NewswireTheravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on...
2y agoTBPHTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024PR NewswireTheravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to ...
2y agoTBPHTheravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts